The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation

Experimental Hematology

Volumn 27, Issue 12, 1999, Pages 1796-1805

  Hübinger, Gabriele ^a   Scheffrahn, Inka ^b   Müller, Elke ^a   Bai, Renyuan ^c   Duyster, Justus ^c   Morris, Stephan W ^d   Schrezenmeier, Hubert ^a   Bergmann, Lothar ^a  

^a UNIVERSITY OF ULM   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Anaplastic large cell lymphoma; CD30; NPM ALK; Tumor necrosis factor receptor

Indexed keywords

CD30 ANTIGEN; CYTOKINE RECEPTOR; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR RECEPTOR;

ANAPLASTIC CARCINOMA; ARTICLE; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT;

ANTIGENS, CD30; ENZYME ACTIVATION; HUMANS; LYMPHOMA, LARGE-CELL, KI-1; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0344822643     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(99)00116-2     Document Type: Article

References (37)

1. Stansfeld A.G., Diebold J., Kapanci G., Lennert K., Mioduszewska O., Noel R., Rike F., Sundstorm C., van Unnik J.A.M., Wright D.H. Updated Kiel classification for lymphomas. Lancet. 1:1988;292.
2. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K.C., Cleary M.L., Delsol G., De Wolf-Peters C., Falini B., Gatter K.C., Grogan T.M., Isaacson P.G., Knowles D.M., Mason D.Y., Müller-Hermelink H.K., Pileri S.A., Ralfkiaer E., Warnke R.A. A revised European-American classification of lymphoid neoplasms. a proposal from the international lymphoma study group Blood. 84:1994;1361.
3. Shulman L.N., Frisard B., Antin J.H., Weeler C., Pinkus G., Magauran N., Mauch P., Nobles E., Mashal R., Canellos G., Tung N., Kadin M.E. Primary Ki-1 anaplastic large-cell lymphoma in adults. clinical characteristics and therapeutic outcome J Clin Oncol. 11:1993;937.
4. Massimino M., Gasparini M., Giardini R. Ki-1 (CD30) anaplastic large-cell lymphoma in children. Ann Oncol. 6:1995;915.
5. Sarris A.H., Luthra R., Papadimitracopoulou V., Waasdorp M., Dimopoulos M.A., McBride J.A., Cabanillas F., Duvic M., Deisseroth A., Morris S.W., Pugh W.C. Amplification of genomic DNA demonstrates the presence of the t(2;5)(p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood. 88:1996;1771.
6. Mathew P., Sanger W.G., Weisenburger D.D., Valentine M., Valentine V., Pickering D., Higgins C., Hess M., Cui X., Srivastava D.K., Morris S.W. Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization. Blood. 89:1997;1678.
7. Morris S.W., Kirstein M.N., Valetine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., Look A.T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 263:1994;1281.
8. Morris S.W., Naeve C., Mathew P., James P.L., Kirstein M.N., Cui X., Witte D.P. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 14:1997;2175.
9. Pulford K., Lamant L., Morris S.W., Butler L.H., Wood K.M., Stroud D., Delsol G., Mason D.Y. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 89:1997;1394.
10. Iwahara T., Fujimoto J., Wen D., Cupples R., Bucay N., Arakawa T., Mori S., Ratzkin B., Yamamoto T. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 14:1997;439.
11. Shiota M., Nakamura S., Ichinohasama R., Abe M., Akagi T., Takeshita M., Mori N., Fujimoto J., Miyauchi J., Mikata A. Anaplastic large-cell lymphomas expressing the novel chimeric protein p80NPM/ALK. a distinct clinicopathologic entity Blood. 86:1995;1954.
12. Pittaluga S., Wiodarska I., Pulford K., Campo E., Morris S.W., Van den Berghe H., De Wolf-Peeters C. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol. 151:1997;343.
13. Benharroch D., Meguerian-Bedoyan Z., Lamant L., Amin C., Brugieres L., Terrier-Lacombe M.J., Haralambieva E., Pulford K., Pileri S., Morris S.W., Mason D.Y., Delsol G. ALK-positive lymphoma. a single disease with a broad spectrum of morphology Blood. 91:1998;2076.
14. Shiota M., Fujimoto J., Semba T., Satoh H., Yamamoto T., Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to LTK in a human Ki-1 lymphoma cell line, AMS3. Oncogene. 9:1994;1567.
15. Fujimoto J., Shiota M., Iwahara T., Seki N., Satoh H., Mori S., Yamamoto T. Characterization of th transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A. 93:1996;4181.
16. Bischof D., Pulford K., Mason D.Y., Morris S.W. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 17:1997;2312.
17. Kuefer M.U., Look A.T., Pulford K., Behm F.G., Pattengale P.K., Mason D.Y., Morris S.W. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood. 90:1997;2901.
18. Bai R., Dieter P., Peschel C., Morris S.W., Duyster J. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large cell lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediated its mitogenicity. Mol Cel Biol. 18:1998;6951.
19. Stein H., Mason D.Y., Gerdes J., O'Connor N., Wainscoat J., Pallesen G., Gatter K., Falini B., Delsol G., Lemke H., Schwarting R., Lennert K. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue. evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells Blood. 66:1985;848.
20. Dürkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 68:1992;421.
21. Baldwin A.S. The NFκB and IκB proteins. new discoveries and insights Annu Rev Immunol. 14:1996;649.
22. Horie R., Aizawa S., Nagi M., Ito K., Higashihara M., Ishida T., Inoue J., Watanabe T. A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation. Int Immunol. 10:1998;203.
23. Lee S.Y., Park C.G., Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med. 183:1996;669.
24. Tian Z.G., Longo D.L., Funakoshi S., Asai O., Ferris D.K., Widmer M., Murphy W.J. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res. 55:1995;5335.
25. Amakawa R., Hakem A., Kundig T.M., Matsuyama T., Simard J.J.L., Timms E., Wakeham A., Mittruecker H.W., Griesser H., Takimoto H., Schmits R., Shahinain A., Ohashi P., Penninger J.M., Mak T.W. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell. 84:1996;551.
26. Gedrich R.W., Gilfillan M.C., Duckett C.S., Van Dongen J.L., Thompson C.B. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem. 271:1996;12852.
27. Lee S.Y., Lee S.Y., Kandala G., Liou M.L., Liou H.C., Choi Y. CD30/TNF receptor-associated factor interaction. NF-κB activation and binding specificity Proc Natl Acad Sci U S A. 93:1996;9699.
28. Duckett C.S., Gedrich R.W., Gilfillan M.C., Thompson C.B. Induction of nuclear factor κB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol. 17:1997;1535.
29. Boucher L.M., Marengere L.E.M., Lu Y., Thukral S., Mak T.W. Binding sites of cytoplasmic effectors TRAF1, 2 and 3 on CD30 and other members of the TNF receptor superfamily. Biochem Biophys Res Commun. 233:1997;592.
30. Fischer P., Nacheva E., Mason D.Y., Sherrington P.D., Hoyle C., Hayhoe F.G.J., Karpas A. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor β-chain gene. Blood. 72:1988;234.
31. Drexler H.G., Gaedicke G., Lok M.S., Diehl V., Minowada J. Hodgkin's disease derived cell lines HDLM-2 and L-428. comparison of morphology, immunological and isoenzyme profiles Leuk Res. 10:1986;487.
32. Gruss H.J., Boiani N., Williams D.E., Armitage R.J., Smith C.A., Goodwin R.G. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 83:1994;2045.
33. Kaye K.M., Devergne O., Harade J.N., Izumi K.M., Yalamanchili R., Kieff E., Mosialos G. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A. 93:1996;11085.
34. Stamenkovic I., Clark E.A., Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J. 9:1989;1403.
35. Jung W., Krueger S., Renner C., Gause A., Sahin U., Trümper L., Pfreundschuh M. Opposite effects of the CD30 ligand are not due to CD30 mutations. results from cDNA cloning and sequence comparison of the CD30 antigen from different sources Mol Immunol. 31:1994;1329.
36. Soler C., Beguinot L., Carpenter G. Individual epidermal growth factor receptor autophosphorylation sites do not stringently define association motifs for several SH2-containing proteins. J Biol Chem. 269:1994;12320.
37. Faris M., Gaskin F., Parson J.T., Fu S.M. CD40 signaling pathway. anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylated proteins including protein tyrosine kinase Lyn, Fyn, and Syk and the appearance of a 28-kD tyrosine phosphorylated protein J Exp Med. 179:1994;1923.